Patents by Inventor Samuel S. Murray
Samuel S. Murray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9855368Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: March 6, 2015Date of Patent: January 2, 2018Assignees: The Regents of the University of California, Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang, Keyvan Behnam
-
Patent number: 9694047Abstract: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical co-morbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.Type: GrantFiled: June 30, 2015Date of Patent: July 4, 2017Assignee: The Regents of the University of CaliforniaInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey Wang, Keyvan Behnam
-
Patent number: 9610320Abstract: The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.Type: GrantFiled: June 5, 2015Date of Patent: April 4, 2017Assignees: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Keyvan Behnam, Jeffrey C. Wang
-
Patent number: 9333237Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: April 28, 2014Date of Patent: May 10, 2016Assignees: The United States of America National Institutes of Health (NIH), U.S. Dept of Health and Human Services (DHHS), The Regents of the University of CaliforniaInventors: Samuel S. Murray, Elsa J. Murray, Keyvan Behnam
-
Publication number: 20160000860Abstract: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.Type: ApplicationFiled: June 30, 2015Publication date: January 7, 2016Inventors: Samuel S. Murray, Elsa J. Murray, Jeffrey Wang, Keyvan Behnam
-
Publication number: 20150265673Abstract: The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.Type: ApplicationFiled: June 5, 2015Publication date: September 24, 2015Inventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Keyvan Behnam, Jeffrey C. Wang
-
Publication number: 20150246158Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: ApplicationFiled: March 6, 2015Publication date: September 3, 2015Inventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang, Keyvan Behnam
-
Patent number: 9072709Abstract: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.Type: GrantFiled: June 23, 2010Date of Patent: July 7, 2015Assignees: The Regents of the University of California, The United States of America Represented by The Department of Veterans AffairsInventors: Samuel S. Murray, Elsa Murray, Jeffrey Wang, Keyvan Behnam
-
Patent number: 9050300Abstract: The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.Type: GrantFiled: April 5, 2013Date of Patent: June 9, 2015Assignees: The Regents of The University of California, The United States of America Represented by The Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Keyvan Behnam, Jeffrey C. Wang
-
Patent number: 8975231Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: June 1, 2012Date of Patent: March 10, 2015Assignees: The Regents of the University of California, The United States of America represented by the Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Jeffrey Wang, Keyvan Behnam
-
Publication number: 20150056700Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: ApplicationFiled: April 28, 2014Publication date: February 26, 2015Applicants: The Regents of The University of California, United States Government Represented by The Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Murray, Keyvan Behnam
-
Patent number: 8962569Abstract: Provided herein is tumor suppression composition and methods of making and using the same.Type: GrantFiled: May 25, 2011Date of Patent: February 24, 2015Assignees: The Regeants of the University of California, The United States of America as Represented by the Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang
-
Patent number: 8759296Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: May 25, 2012Date of Patent: June 24, 2014Assignees: The Regents of The University of California, The United States of America as Represented by The Department of Veterans AffairsInventors: Samuel S. Murray, Keyvan Behnam, Elsa J. Brochmann-Murray
-
Patent number: 8753660Abstract: Demineralized bone matric (DBM) and native bone morphogenetic protein (nBMP) are complex mixtures of non-collagenous bone proteins. These mixtures contain many of the BMPs that are available as recombinant molecules. Information regarding the presence in these materials of molecules that may affect the availability and activity of the BMPs is very limited. A chemical extraction of DBM, such as using alkali-urea produces a water soluble extractate which inhibits the osteogenic activity of DBM. Noggin, an extracellular BMP ligand antagonist is found in the water soluble extractate from DBM. Differential chemical extraction is a useful means of removing non-osteogenic, or osteogenic inhibitory molecules from DBM and nBMP.Type: GrantFiled: November 29, 2005Date of Patent: June 17, 2014Assignees: The Regents of The University of California, The United States of America as Represented by The Department of Veterans AffairsInventors: Keyvan Behnam, Elsa J. Brochmann-Murray, Samuel S. Murray
-
Publication number: 20130303449Abstract: The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.Type: ApplicationFiled: April 5, 2013Publication date: November 14, 2013Inventors: Samuel S. MURRAY, Elsa J. BROCHMANN-MURRAY, Keyvan BEHNAM, Jeffrey C. WANG
-
Publication number: 20130143811Abstract: Provided herein is tumor suppression composition and methods of making and using the same.Type: ApplicationFiled: May 25, 2011Publication date: June 6, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang
-
Publication number: 20130095139Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: ApplicationFiled: June 1, 2012Publication date: April 18, 2013Applicants: Department of Veterans Affairs, The Regents of the University of CaliforniaInventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Jeffrey Wang, Keyvan Behnam
-
Publication number: 20130095075Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: ApplicationFiled: May 25, 2012Publication date: April 18, 2013Applicants: DEPARTMENT OF VETERANS AFFAIRS, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Samuel S. Murray, Keyvan Behnam, Elsa J. Brochman-Murray
-
Patent number: 8415302Abstract: The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.Type: GrantFiled: December 26, 2007Date of Patent: April 9, 2013Assignees: The Regents of the University of California, The United States of America as Represented by the Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Keyvan Behnam, Jeffrey C. Wang
-
Publication number: 20120184490Abstract: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.Type: ApplicationFiled: June 23, 2010Publication date: July 19, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Samuel S. Murray, Elsa Murray, Jeffrey Wang, Keyvan Behnam